Literature DB >> 20413960

Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?

Hiddo J Lambers Heerspink1, Dick de Zeeuw.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20413960     DOI： 10.1159/000292501

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN： 0250-8095            Impact factor:   3.754


× No keyword cloud information.
  18 in total

Review 1.  Epidemiology of hypertensive kidney disease.

Authors:  Suneel Udani; Ivana Lazich; George L Bakris
Journal:  Nat Rev Nephrol       Date:  2010-11-16       Impact factor: 28.314

2.  Visit-to-visit blood pressure variability is related to albuminuria variability and progression in patients with type 2 diabetes.

Authors:  S Noshad; M Mousavizadeh; M Mozafari; M Nakhjavani; A Esteghamati
Journal:  J Hum Hypertens       Date:  2013-07-11       Impact factor: 3.012

Review 3.  A perspective on chronic kidney disease progression.

Authors:  Jianyong Zhong; Hai-Chun Yang; Agnes B Fogo
Journal:  Am J Physiol Renal Physiol       Date:  2016-12-14

Review 4.  Proteomic urinary biomarker approach in renal disease: from discovery to implementation.

Authors:  Joost P Schanstra; Harald Mischak
Journal:  Pediatr Nephrol       Date:  2014-03-15       Impact factor: 3.714

Review 5.  Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment.

Authors:  Federica Barutta; Graziella Bruno; Serena Grimaldi; Gabriella Gruden
Journal:  Endocrine       Date:  2014-10-02       Impact factor: 3.633

6.  Urinary exosomes as a novel biomarker for evaluation of α-lipoic acid's protective effect in early diabetic nephropathy.

Authors:  Hanxiao Sun; Weifeng Yao; Yubin Tang; Wenfang Zhuang; Dan Wu; Shan Huang; Huiming Sheng
Journal:  J Clin Lab Anal       Date:  2017-01-23       Impact factor: 2.352

7.  Biomarkers and surrogate endpoints in kidney disease.

Authors:  Erum A Hartung
Journal:  Pediatr Nephrol       Date:  2015-05-16       Impact factor: 3.714

8.  Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.

Authors:  Justyna Siwy; Joost P Schanstra; Angel Argiles; Stephan J L Bakker; Joachim Beige; Petr Boucek; Korbinian Brand; Christian Delles; Flore Duranton; Beatriz Fernandez-Fernandez; Marie-Luise Jankowski; Mohammad Al Khatib; Thomas Kunt; Maria Lajer; Ralf Lichtinghagen; Morten Lindhardt; David M Maahs; Harald Mischak; William Mullen; Gerjan Navis; Marina Noutsou; Alberto Ortiz; Frederik Persson; John R Petrie; Johannes M Roob; Peter Rossing; Piero Ruggenenti; Ivan Rychlik; Andreas L Serra; Janet Snell-Bergeon; Goce Spasovski; Olivera Stojceva-Taneva; Matias Trillini; Heiko von der Leyen; Brigitte M Winklhofer-Roob; Petra Zürbig; Joachim Jankowski
Journal:  Nephrol Dial Transplant       Date:  2014-03-02       Impact factor: 5.992

Review 9.  Proteomics and systems biology for understanding diabetic nephropathy.

Authors:  Jonathan M Starkey; Ronald G Tilton
Journal:  J Cardiovasc Transl Res       Date:  2012-05-12       Impact factor: 4.132

10.  Discovery and verification of urinary peptides in type 2 diabetes mellitus with kidney injury.

Authors:  Guangzhen Fu; Ye Du; Lina Chu; Man Zhang
Journal:  Exp Biol Med (Maywood)       Date:  2016-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.